Icon Advisers Inc. Co. bought a new position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 77,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,877,000. Icon Advisers Inc. Co. owned about 0.15% of Supernus Pharmaceuticals as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of SUPN. Legal & General Group Plc increased its stake in Supernus Pharmaceuticals by 3.1% during the first quarter. Legal & General Group Plc now owns 104,580 shares of the specialty pharmaceutical company’s stock worth $4,791,000 after acquiring an additional 3,120 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 423,062 shares of the specialty pharmaceutical company’s stock valued at $19,376,000 after buying an additional 13,238 shares in the last quarter. Allianz Asset Management GmbH grew its stake in shares of Supernus Pharmaceuticals by 60.3% in the first quarter. Allianz Asset Management GmbH now owns 278,701 shares of the specialty pharmaceutical company’s stock valued at $12,765,000 after buying an additional 104,829 shares in the last quarter. Cim LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at $207,000. Finally, Bank of Montreal Can grew its stake in shares of Supernus Pharmaceuticals by 111.5% in the second quarter. Bank of Montreal Can now owns 79,922 shares of the specialty pharmaceutical company’s stock valued at $4,783,000 after buying an additional 42,138 shares in the last quarter. 99.10% of the stock is owned by institutional investors.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $46.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, July 25th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, September 14th. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th. Finally, ValuEngine raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. Supernus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $54.78.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.10. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The firm had revenue of $102.99 million during the quarter, compared to analysts’ expectations of $100.75 million. During the same period in the previous year, the firm posted $0.29 EPS. Supernus Pharmaceuticals’s revenue for the quarter was up 28.1% on a year-over-year basis. As a group, research analysts anticipate that Supernus Pharmaceuticals Inc will post 1.93 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.wkrb13.com/2018/11/07/77000-shares-in-supernus-pharmaceuticals-inc-supn-acquired-by-icon-advisers-inc-co.html.
Supernus Pharmaceuticals Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
See Also: What is a Reverse Stock Split?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.